Dr Reddy's is all set to witness manifold increase in its US generic sales for the current fiscal, thanks to its fluoxetine 40 mg capsules launch with 180-day marketing exclusively.
According to the research report, Dr Reddy's is likely to post US generics sales of over $50 million (Rs 240 crore) in 2001-02.
It is expected to go up to $68 million in the next fiscal.
Out of the $50 million projection for the current fiscal, a highly significant amount is expected from fluoxetine 40 mg capsules, which was launched on August 3, 2001.
The company recorded a sales turnover of Rs 30.3 crore from US generics during last fiscal, the first year of its launch, and Rs 26.1 crore in the first quarter of the current fiscal.
The company has so far filed 14 ANDAs with US FDA and launched six products in the US generics market. These are: ranitidine 75 mg tablets (OTC), ranitidine 150 mg and 300 mg capsules, famotidine 20 mg and 40 mg tablets, oxaprozin 600 mg tablets, fluoxetine 40 mg capsules and famotidine 10 mg tablets (OTC).
Dr Reddy's has tentative ANDA approvals for ciprofloxacin 100 mg, 250 mg, 500 mg and 750 mg tablets, omeprazole 40 mg capsules, fluoxetine 10 mg and 20 mg capsules and 10 mg tablets.
It believes that it has the first-to- file status for omeprazole 40 mg capsules, ciprofloxacin 100 mg tablets, olanzapine 20 mg tablets and ondansetron 4 mg, 8 mg and 24 mg tablets.